Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Blanc

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
BMJ Open|June 27, 2019
How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 yearsStéphane Epelbaum, Claire Paquet, Jacques Hugon, et al.
NPJ Parkinson'S Disease|January 20, 2023
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodiesAnna Inguanzo, Konstantinos Poulakis, Rosaleena Mohanty, et al.
Research Square|February 7, 2023
Sex differences in brain atrophy in dementia with Lewy bodiesJavier Oltra, Annegret Habich, Christopher G Schwarz, et al.
Gastroenterology|December 13, 2016
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant TransformationJean-Charles Nault, Gabrielle Couchy, Charles Balabaud, et al.
Future Oncology (London, England)|April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Hepatology (Baltimore, Md.)|April 8, 2026
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)Pierre Nahon, Marianne Ziol, Long Pan, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Alzheimer'S Research & Therapy|July 19, 2022
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohortFrederic Blanc, Vincent Bouteloup, Claire Paquet, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 22, 2023
Sex differences in brain atrophy in dementia with Lewy bodiesJavier Oltra, Annegret Habich, Christopher G Schwarz, et al.
Neurology|September 29, 2020
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodiesDaniel Ferreira, Scott A Przybelski, Timothy G Lesnick, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
BMJ Open|June 27, 2019
How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 yearsStéphane Epelbaum, Claire Paquet, Jacques Hugon, et al.
NPJ Parkinson'S Disease|January 20, 2023
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodiesAnna Inguanzo, Konstantinos Poulakis, Rosaleena Mohanty, et al.
Research Square|February 7, 2023
Sex differences in brain atrophy in dementia with Lewy bodiesJavier Oltra, Annegret Habich, Christopher G Schwarz, et al.
Gastroenterology|December 13, 2016
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant TransformationJean-Charles Nault, Gabrielle Couchy, Charles Balabaud, et al.
Future Oncology (London, England)|April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Hepatology (Baltimore, Md.)|April 8, 2026
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)Pierre Nahon, Marianne Ziol, Long Pan, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Alzheimer'S Research & Therapy|July 19, 2022
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohortFrederic Blanc, Vincent Bouteloup, Claire Paquet, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 22, 2023
Sex differences in brain atrophy in dementia with Lewy bodiesJavier Oltra, Annegret Habich, Christopher G Schwarz, et al.
Neurology|September 29, 2020
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodiesDaniel Ferreira, Scott A Przybelski, Timothy G Lesnick, et al.
Pageof 9